UY30419A1 - Nuevos benzoxazoles heteroaril sustituidos - Google Patents

Nuevos benzoxazoles heteroaril sustituidos

Info

Publication number
UY30419A1
UY30419A1 UY30419A UY30419A UY30419A1 UY 30419 A1 UY30419 A1 UY 30419A1 UY 30419 A UY30419 A UY 30419A UY 30419 A UY30419 A UY 30419A UY 30419 A1 UY30419 A1 UY 30419A1
Authority
UY
Uruguay
Prior art keywords
substituted
heteroaril
alzheimer
disease
compositions
Prior art date
Application number
UY30419A
Other languages
English (en)
Spanish (es)
Inventor
Can Slivo
David Pyring
Sohn Daniel
Wensbo David-Edwards
Britt-Marie Swahn
Malmstrom Jonas
Original Assignee
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=38833677&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=UY30419(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab
Publication of UY30419A1 publication Critical patent/UY30419A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Hospice & Palliative Care (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Psychiatry (AREA)
  • Obesity (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
UY30419A 2006-06-19 2007-06-18 Nuevos benzoxazoles heteroaril sustituidos UY30419A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US81493606P 2006-06-19 2006-06-19

Publications (1)

Publication Number Publication Date
UY30419A1 true UY30419A1 (es) 2008-01-31

Family

ID=38833677

Family Applications (1)

Application Number Title Priority Date Filing Date
UY30419A UY30419A1 (es) 2006-06-19 2007-06-18 Nuevos benzoxazoles heteroaril sustituidos

Country Status (16)

Country Link
US (1) US7670591B2 (enExample)
EP (1) EP2035418A1 (enExample)
JP (1) JP5548842B2 (enExample)
KR (1) KR20090021224A (enExample)
CN (1) CN101506201B (enExample)
AR (1) AR061515A1 (enExample)
AU (1) AU2007261786A1 (enExample)
CA (1) CA2655084A1 (enExample)
CL (1) CL2007001784A1 (enExample)
IL (1) IL195669A0 (enExample)
MX (1) MX2008015718A (enExample)
NO (1) NO20090201L (enExample)
TW (1) TW200813035A (enExample)
UY (1) UY30419A1 (enExample)
WO (1) WO2007149030A1 (enExample)
ZA (1) ZA200810163B (enExample)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW201018678A (en) 2006-01-27 2010-05-16 Astrazeneca Ab Novel heteroaryl substituted benzothiazoles
TW200901998A (en) 2007-03-06 2009-01-16 Astrazeneca Ab Novel 2-heteroaryl substituted benzothiophenes and benzofuranes
ES2554772T3 (es) * 2008-05-30 2015-12-23 Merck Sharp & Dohme Corp. Azabenzoxazoles sustituidos novedosos
US20110212031A1 (en) * 2008-10-31 2011-09-01 Cyrille Sur Novel substituted azabenzoxazoles
US8779149B2 (en) 2010-08-23 2014-07-15 Syntrix Biosystems, Inc. Aminopyridine- and aminopyrimidinecarboxamides as CXCR2 modulators
WO2012080729A2 (en) * 2010-12-14 2012-06-21 Electrophoretics Limited CASEIN KINASE 1δ (CK1δ) INHIBITORS
WO2014132919A1 (ja) * 2013-02-28 2014-09-04 国立大学法人京都大学 診断用組成物
KR101499329B1 (ko) * 2013-06-17 2015-03-06 주식회사 대웅제약 (2-(3,4-다이메톡시페닐)-5-(3-메톡시프로필)벤조퓨란)의결정형 및 이의 제조방법
JP6149684B2 (ja) * 2013-10-21 2017-06-21 ブラザー工業株式会社 携帯端末、画像処理装置、及びプログラム
WO2015112048A1 (en) * 2014-01-24 2015-07-30 Huawei Technologies Co., Ltd. Method and device for cross-polarization interference suppression
CN104059028B (zh) * 2014-06-06 2020-10-16 北京智博高科生物技术有限公司 与Aβ斑块具有亲和力的含手性侧链取代的氟代2-芳基苯并杂环化合物、其制备方法及应用
KR101709731B1 (ko) * 2015-05-22 2017-02-23 한국과학기술연구원 벤조옥사졸 또는 벤조티아졸 화합물, 그의 제조, 및 용도
US10324943B2 (en) * 2015-08-10 2019-06-18 Business Objects Software, Ltd. Auto-monitoring and adjustment of dynamic data visualizations
JP7114074B2 (ja) * 2015-08-18 2022-08-08 ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア 画像化のためのニトロキシドを含むアミロイド結合剤およびその治療的使用
KR101812424B1 (ko) * 2016-12-28 2017-12-27 충북대학교 산학협력단 2-(2-아미노-5-(1-(피퍼리딘-4-일)-1H-피라졸-3-일)피리딘-3-일)벤조[d]옥사졸-6-올 및 이를 유효성분으로 포함하는 치매의 예방 및 치료용 조성물
CA3166429A1 (en) * 2020-01-28 2021-08-05 Bradley Dean Tait Compounds, compositions and methods for stabilizing transthyretin and inhibiting transthyretin misfolding

Family Cites Families (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU523040B2 (en) 1978-05-15 1982-07-08 Kanebo Limited Calcium -antagonistic composition
GB8305245D0 (en) 1983-02-25 1983-03-30 Fujisawa Pharmaceutical Co Imidazo-heterocyclic compounds
JPS6394248A (ja) * 1986-10-08 1988-04-25 Canon Inc 電子写真感光体
CA2034309C (en) 1990-01-22 1997-04-01 Takashi Iwaki Mesomorphic compound, liquid crystal composition containing same, liquid crystal device using same and display apparatus
JPH09507071A (ja) 1993-12-21 1997-07-15 イーライ・リリー・アンド・カンパニー アミロイド原性ペプチドに関連した状態を治療又は予防する方法
US5518713A (en) * 1995-02-13 1996-05-21 3V Inc. Benzoxazole derivatives, the use thereof as sunscreens and cosmetic compositions containing them
JPH11116476A (ja) 1997-10-16 1999-04-27 Sankyo Co Ltd 縮合複素環化合物
HU230581B1 (hu) 2000-08-24 2017-01-30 University Of Pittsburgh - Of The Commonwealth System Of Higher Education Tioflavin-származékok és alkalmazásuk az Alzheimer-kór diagnózisában és kezelésében
JP2004524289A (ja) 2000-12-22 2004-08-12 アストラゼネカ・アクチエボラーグ 治療化合物
US6596731B2 (en) 2001-03-27 2003-07-22 Hoffmann-La Roche Inc. Substituted imidazo[1,2-A] pyridine derivatives
DE60217090T2 (de) 2001-04-23 2007-07-12 The Trustees Of The University Of Pennsylvania Amyloid plaque aggregationshemmer und diagnostische bilderzeugungsmittel
EP1460067A4 (en) * 2001-11-26 2005-12-07 Takeda Pharmaceutical BICYCLIC DERIVATIVES, PROCESS FOR THEIR PREPARATION AND THEIR USE
GB0130305D0 (en) 2001-12-19 2002-02-06 Amersham Plc Compounds for imaging alzheimers disease
AU2003242233A1 (en) 2002-06-12 2003-12-31 Bf Research Institute, Inc. Probe compound for image diagnosis of disease with amyloid accumulation, compound for staining age spots/diffuse age spots, and remedy for disease with amyloid accumulation
TW200401194A (en) 2002-07-11 2004-01-16 Advanced Micro Devices Inc Method and apparatus for determining a processor state without interrupting processor operation
EP1539151B1 (en) 2002-08-02 2009-03-18 Genesoft Pharmaceuticals, Inc. Biaryl compounds having anti-infective activity
JP2004250411A (ja) 2003-02-21 2004-09-09 Bf Kenkyusho:Kk アミロイドβ蓄積性疾患の診断プローブおよび治療用化合物
CA2438032C (en) 2003-03-14 2013-05-07 University Of Pittsburgh Benzothiazole derivative compounds, compositions and uses
CA2521056A1 (en) 2003-03-31 2004-10-14 Daiichi Pharmaceutical Co., Ltd. Hydrazone derivative
RU2340612C2 (ru) 2003-05-13 2008-12-10 Ф.Хоффманн-Ля Рош Аг 2-имидазобензотиазолы как лиганды аденозинового рецептора
CA2830939C (en) 2004-07-02 2017-02-28 University Of Pittsburgh - Of The Commonwealth System Of Higher Education Use of thioflavin radiolabelled derivatives in amyloid imaging for identifying patients prodromal to a disease associated with amyloid deposition
GB0420722D0 (en) 2004-09-17 2004-10-20 Addex Pharmaceuticals Sa Novel allosteric modulators
CA2609980C (en) 2005-05-27 2015-10-13 Queen's University At Kingston Treatment of protein folding disorders
US20080219922A1 (en) 2005-09-12 2008-09-11 Goodman Mark M Alzheimer's Disease Imaging Agents
CN101355940B (zh) 2005-09-16 2013-03-27 匹兹堡大学高等教育联邦体系 用于检测具有至少一种促淀粉样变蛋白的淀粉样沉积物的体内或体外方法
WO2007047204A1 (en) 2005-10-11 2007-04-26 University Of Pittsburgh Isotopically-labeled benzofuran compounds as imagingagents foramyloidogenic proteins
US8022075B2 (en) 2005-11-30 2011-09-20 Fujifilm Ri Pharma Co., Ltd. Diagnostic and remedy for disease caused by amyloid aggregation and/or deposition
TW201018678A (en) 2006-01-27 2010-05-16 Astrazeneca Ab Novel heteroaryl substituted benzothiazoles
EP1986633B1 (en) * 2006-02-10 2014-07-30 Summit Corporation Plc Treatment of duchenne muscular dystrophy
EP2023919A4 (en) 2006-05-08 2010-12-22 Molecular Neuroimaging Llc COMPOUNDS AND AMYLOID PROBES FOR THERAPY AND IMAGING USES
EP2125800A1 (en) 2007-01-22 2009-12-02 AstraZeneca AB Novel heteroaryl substituted imidazo ý1,2 -a¨pyridine derivatives

Also Published As

Publication number Publication date
JP2009541309A (ja) 2009-11-26
WO2007149030A8 (en) 2008-02-28
WO2007149030A1 (en) 2007-12-27
MX2008015718A (es) 2008-12-19
AR061515A1 (es) 2008-09-03
JP5548842B2 (ja) 2014-07-16
CN101506201A (zh) 2009-08-12
EP2035418A1 (en) 2009-03-18
AU2007261786A1 (en) 2007-12-27
ZA200810163B (en) 2010-05-26
US7670591B2 (en) 2010-03-02
NO20090201L (no) 2009-01-13
CN101506201B (zh) 2012-03-14
TW200813035A (en) 2008-03-16
CA2655084A1 (en) 2007-12-27
KR20090021224A (ko) 2009-02-27
US20080027051A1 (en) 2008-01-31
IL195669A0 (en) 2009-09-01
CL2007001784A1 (es) 2008-01-18

Similar Documents

Publication Publication Date Title
UY30419A1 (es) Nuevos benzoxazoles heteroaril sustituidos
ECSP088645A (es) Nuevos benzotiazoles sustituidos con heteroaril
WO2009155017A3 (en) Novel substituted azabenzoxazoles
MX375282B (es) Pirrolo[2,3-c]piridinas como agentes de formacion de imagenes para ovillos neurofibrilares.
MX2009007487A (es) Derivados de imidazo[1,2-a]piridina substituidos de heteroarilo novedosos.
UY30951A1 (es) Benzofuranos y benzotiofenos 2-heteroaril sustituidos novedosos 709
CL2012000708A1 (es) Compuestos derivados de imidazopiridina o imidazopirimidina, inhibidores de pde10a; proceso de preparacion de dichos compuestos; composiciones farmaceuticas; y su uso para el tratamiento terapeutico y/o preventivo de trastornos psicoticos, esquizofrenia, enfermedad de alzheimer, tumores solidos, entre otras enfermedades.
EA201101243A1 (ru) 3h-имидазо[4,5-c]пиридин-6-карбоксамиды в качестве противовоспалительных средств
EP2166854A4 (en) TRIAZONE DERIVATIVES FOR THE TREATMENT OF MORBUS ALZHEIMER AND RELATED SUFFERINGS
SV2011003939A (es) Piridiloxi-indoles inhibidores del vegf-r2 y uso de los mismos para el tratamiento de enfermedades
BRPI0515175A (pt) método para radiofluoração, composto, composição radiofarmacêutica, uso de um conjugado radiorrotulado ou um sal do mesmo, método para diagnose ou formação de imagem in vivo de uma doença ou condição associada com a angiogênese, e, método para monitorar o efeito do tratamento de um corpo humano ou animal com um medicamento para combater uma condição associada com cáncer
EP2135613A4 (en) MEDICAMENT AND DIAGNOSIS FOR BRAIN DISEASE DUE TO MITOCHONDRIAL DYSFUNCTION
AR114029A2 (es) Compuestos adecuados como precursores de compuestos que son útiles para obtener imágenes de depósitos amiloides, usos y procesos
EP2198292A4 (en) IMPROVED MORBUS ALZHEIMER DIAGNOSIS
BRPI1014595A2 (pt) procedimento de obtenção de novos derivados naftaleno para o diagnóstico in vivo de doença de alzheimer
EP2365974A4 (en) FLUORATED BENZOTHIAZOL DERIVATIVES, METHOD FOR THE PRODUCTION THEREOF AND IMAGE-DISPLAYING AGENT FOR THE DIAGNOSIS OF ALZHEIMER DISEASE, WHICH USES THEREOF
WO2010051196A8 (en) Novel substituted azabenzoxazoles
CL2011000520A1 (es) Compuestos derivados de piperazina; uso para preparar un medicamento util para tratar la enfermedad de alzheimaer, un trastorno neurodegenerativo y amiloidosis; metodo de preparacion de compuestos.
BRPI0808090A2 (pt) Composto, composição farmacêutica, e, método in vivo para medir depósitos de amilóide em um paciente
RU2007118691A (ru) Применение 4-трифторметилфениламида (z)-2-циано-3-гидрокси-бут-2-еновой кислоты для лечения воспалительных заболеваний кишечника
ECSP099082A (es) Beta-agonistas enantioméricamente puros, procedimientos para su preparación y su uso como medicamentos
HN2009003463A (es) Derivados de n5-(2-etoxi-etil)-n3-(2- piridinil) -3,5- piperidin-dicarboxamida para usarse como inhibidores de renina
MX2025010406A (es) Aglutinantes de alfa-sinucleina y metodos de uso
MX2025009562A (es) Enlazadores de alfa-sinucleína y métodos de uso
TH112395A (th) สารประกอบชนิดใหม่ที่เหมาะสมเป็นพรีเคอเซอร์ไปเป็นสารประกอบที่มีประโยชน์สำหรับการถ่ายภาพการสะสมอะมัยลอยด์

Legal Events

Date Code Title Description
109 Application deemed to be withdrawn

Effective date: 20170711